​

​

Three Months Ended June 30,

​

​

Six Months Ended June 30, 

​

2025

​

2024

​

2025

​

2024

Operating expenses:

​

​

​

​

​

​

​

​

​

​

​

Employee related expense

$

32,484

​

$

16,120

​

$

55,422

​

$

32,200

External R&D expense - Apitegromab

​

27,956

​

​

17,082

​

​

47,257

​

​

35,330

External R&D expense - SRK-181

​

792

​

​

3,258

​

​

1,902

​

​

6,005

External R&D expense - SRK-439

​

2,575

​

​

1,550

​

​

6,854

​

​

3,534

External R&D expense - Early research and other

​

2,227

​

​

667

​

​

3,682

​

​

1,409

External expense - G&A

​

14,952

​

​

6,127

​

​

23,895

​

​

11,128

Other segment related expense*

​

6,273

​

​

4,882

​

​

11,531

​

​

9,739

​

​

​

​

​

​

​

​

​

​

​

​

Employee related equity-based compensation expense

​

24,433

​

​

9,312

​

​

37,846

​

​

17,476

Depreciation and amortization expense

​

417

​

​

500

​

​

810

​

​

1,096

​

​

​

​

​

​

​

​

​

​

​

​

Other non-operating expense/(income), net

​

(2,078)

​

​

(990)

​

​

(4,445)

​

​

(2,556)

​

​

​

​

​

​

​

​

​

​

​

​

Net loss

$

110,031

​

$

58,508

​

$

184,754

​

$

115,361

​

​

​

​

​

​

​

​

​

​

​

​